MORE►
cell therapy
Secretome Therapeutics’ leadership team includes, from left: David Chapman, senior vice president of operations; Karin Lucas, Ph.D., vice president of medical affairs; Maggie Loeffler, CPA, vice president of finance and administration; and Marshelle Smith, M.D., chief development officer. [Photos: Secretome Therapeutics]
Secretome Therapeutics Builds Out Rare Disease Leadership Team
by Sandra Engelland | Aug 4, 2026
The Plano company’s lead candidate uses neonatal cardiac progenitor cells to target the heart complications of Duchenne muscular dystrophy.
by Quincy Preston |
Sep 18, 2023
The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.
MORE►
by Lance Murray |
Sep 13, 2019
In this weekly roundup of research and development activity in North Texas, you’ll also read about how an SMU professor and students from Garland High School are using smartphone data to monitor a local bridge’s health.
MORE►
by Lance Murray |
Sep 12, 2019
Together, the two companies aim to increase access to complex medications and ensure that patients more quickly receive the correct drug at the right time.
MORE►
